Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy
Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy
批准号:
9010945
负责人:
MICHAEL T LOTZE
金额:
$31.96万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-01-01 至 2018-12-31
关键词:
AddressAdjuvantApoptosisApoptoticAutophagocytosisBioenergeticsBiological AssayCancer EtiologyCell DeathCell SurvivalCessation of lifeClinicalClinical TrialsCoagulation ProcessCytotoxic ChemotherapyDataDiseaseExcisionFutureGenetic EngineeringHMGB1 geneHealthHistologicHumanHydroxychloroquineIncidenceInflammationInterleukin-6LinkLiverMalignant neoplasm of pancreasMeasuresMediatingMediator of activation proteinMolecularOperative Surgical ProceduresOrganOutcomePaclitaxelPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaParticipantPathway interactionsPatientsPatternPeripheral Blood Mononuclear CellPhasePositron-Emission TomographyProteinsRandomizedRandomized Clinical TrialsRandomized Controlled TrialsResistanceSTAT3 geneSafetyScientistSerum MarkersSignal PathwaySignal TransductionSiteTestingTherapeutic InterventionUnited StatesUniversity of Pittsburgh Cancer Institutebasebody systemcarcinogenesischemotherapyclinical efficacygemcitabineimprovedinhibition of autophagyinhibitor/antagonistmortalitymouse modelneoplastic cellnovelpancreatic neoplasmperipheral bloodpilot trialpre-clinicalpreclinical studyrandomized trialresponsetherapy resistanttumortumor microenvironmenttumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Pancreatic Ductal Adenocarcinoma is a Disease of Excessive Autophagy. Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease characterized by early systemic dissemination, perturbation in bioenergetics, inflammation, coagulation, and resistance to chemotherapy. A common link to explain these tumor associated derangements has eluded clinicians and scientists. In genetically engineered murine models of human pancreatic cancer, we have demonstrated that IL-6 mediated autophagy induced by damage associated molecular pattern proteins (DAMPs) is a critical final pro-survival pathway in the tumor microenvironment promoting carcinogenesis, tumor progression and resistance to therapy. Unexpectedly we have now observed excessive autophagic flux is also present within multiple sites/organ systems in both murine models and patients with PDA. We hypothesize that PDA is a systemic disorder of DAMP induced excessive autophagy. Successful treatment will be associated with a return to homeostatic basal autophagy. Here we propose to directly address this hypothesis in patients by performing a randomized clinical trial of preoperative gemcitabine and nab-paclitaxel with or without the autophagy inhibitor hydroxychloroquine. We have recently completed two 'proof of principle' pilot trials of preoperative gemcitabine/hydroxychloroquine and gemcitabine/nab-paclitaxel; demonstrating the feasibility, safety and the potential for improved efficacy with this approach. We will utilize the clinical outcomes and biologic materials from these three clinical trials to investigate the following specific aims: Specific Aim I: Demonstrate that addition of the autophagy inhibitor hydroxychloroquine improves response to pre-operative gemcitabine and nab-paclitaxel. Specific Aim 2: Demonstrate that addition of the autophagy inhibitor hydroxychloroquine will decrease pro-survival pathways in treated tumors. Specific Aim 3: Demonstrate that PDA is associated with a state of DAMP induced excessive systemic autophagy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy
-
批准号:8612934
-
项目类别:
-
资助金额:$31.58万
-
财政年份:2014
-
负责人:MICHAEL T LOTZE
-
依托单位:
Integrating NK and DC into Cancer Therapy
-
批准号:7938140
-
项目类别:
-
资助金额:$13.73万
-
财政年份:2009
-
负责人:MICHAEL T LOTZE
-
依托单位:
Integrating NK and DC into Cancer Therapy
-
批准号:7499879
-
项目类别:
-
资助金额:$10.74万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
ADMINISTRATIVE CORE
-
批准号:7128914
-
项目类别:
-
资助金额:$23.98万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
Integrating NK and DC into Cancer Therapy
-
批准号:6856364
-
项目类别:
-
资助金额:$167.74万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
Integrating NK and DC into Cancer Therapy
-
批准号:7498417
-
项目类别:
-
资助金额:$162.59万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
Integrating NK and DC into Cancer Therapy
-
批准号:7286420
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
Integrating NK and DC into Cancer Therapy
-
批准号:7091681
-
项目类别:
-
资助金额:$166.38万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
Integrating NK and DC into Cancer Therapy
-
批准号:7678617
-
项目类别:
-
资助金额:$166.26万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
IL-1 HOMOLOGUES PROMOTE THE ACUTE INFLAMMATORY RESPONSE
-
批准号:7128913
-
项目类别:
-
资助金额:$28.17万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
Integrating NK and DC into Cancer Therapy
-
批准号:7286116
-
项目类别:
-
资助金额:$145.83万
-
财政年份:2005
-
负责人:MICHAEL T LOTZE
-
依托单位:
Biological therapeutics program
-
批准号:6664454
-
项目类别:
-
资助金额:$25.04万
-
财政年份:2002
-
负责人:MICHAEL T LOTZE
-
依托单位:
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER
-
批准号:6659255
-
项目类别:
-
资助金额:$16.24万
-
财政年份:2002
-
负责人:MICHAEL T LOTZE
-
依托单位:
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER
-
批准号:6611149
-
项目类别:
-
资助金额:$16.24万
-
财政年份:2001
-
负责人:MICHAEL T LOTZE
-
依托单位:
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER
-
批准号:6493611
-
项目类别:
-
资助金额:$16.24万
-
财政年份:2001
-
负责人:MICHAEL T LOTZE
-
依托单位:
Biological therapeutics program
-
批准号:6503451
-
项目类别:
-
资助金额:$25.04万
-
财政年份:2001
-
负责人:MICHAEL T LOTZE
-
依托单位:
DENDRITIC CELL THERAPIES ELICIT EFFECTIVE ANTITUMOR RESPONSES
-
批准号:6300528
-
项目类别:
-
资助金额:$19.71万
-
财政年份:2000
-
负责人:MICHAEL T LOTZE
-
依托单位:
DENDRITIC CELL THERAPY FOR HIV--ROLE OF CYTOKINES ON ENHANCED T CELL FUNCTION
-
批准号:6347242
-
项目类别:
-
资助金额:$21.39万
-
财政年份:2000
-
负责人:MICHAEL T LOTZE
-
依托单位:
PHASE I MELAN A/MART 1 GP100 TRIAL IN METASTATIC MELANOMA
-
批准号:6304688
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:MICHAEL T LOTZE
-
依托单位:
PHASE 2 STUDY OF FLT3 LIGAND (FLT3) IN METASTATIC MELANOMA PATIENTS
-
批准号:6304636
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:MICHAEL T LOTZE
-
依托单位:
海外基金